José Antonio Mesa Cejudo

Caixa Capital Risc SGEIC SA (Caixa Capital Risc) is a venture capital armof Criteria Caixa SA founded in 2002. The firm is headquartered in Barcelona, Spain with additional offices in Madrid.

Genmedica Therapeutics SL engages in the research and development of new treatments for diabetes. Its has developed novel NCE-generating platform to generate dual action, small molecules that act against oxidative stress and inflammation, two specific pathways known to be critical in the root causes of the disease. The company was founded by Alec Humayun Mian and Luc Marti Clauzel on June 21, 2004 and is headquartered in Barcelona, Spain.

SabirMedical SL is a biomedical research and development company located in the Bioincubator PCB-Santander space at Barcelona Science Park with a clear focus in the development of novel technologies for diagnostics, home and patient care in the field of cardiovascular monitoring. Its technologies cover the design of smart sensors, advanced digital signal processing and machine learning for patient monitoring. In Sabirmedical, they believe that innovation clearly involves the useful application of new inventions and discoveries. For this reason, not only do they manifest its ideas in its inventions (smart sensors and algorithms) but also they successfully apply them in practice (medical assistance workflow).

Omnia Molecular SL engaged in the designing of anti-infective pharmaceuticals. The firm used its proprietary platform to synthesize and develop novel drugs targeted at infections such as mycosis and tuberculosis. The company was founded by Lluís Ribas de Pouplana and Juan Gargallo Costa in 2005 and was headquartered in Barcelona, Spain.

Sanifit Therapeutics SA develops pharmaceuticals for calcification disorders. Its pipeline consists of treatments for calcification disorders, such as calciphylaxis and osteoporosis. The company was founded by Felix Grases in 2004 and is headquartered in Palma de Mallorca, Spain.

Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA.

Sagetis Biotech SL designs and develops drug-delivery technologies. Its polymeric-based platforms are designed to address areas such as" delivery through the blood-brain barrier, genetic material transfection, and tissue regeneration. The company was founded by David Horna, Eduard Diviu Terradas and Salvador Borros Gomez on April 14, 2010, and is headquartered in Barcelona, Spain.

ProRetina Therapeutics SL develops drugs for the treatment of retinal conditions. Its pipeline includes PRO-001 used for the treatment of retinitis pigmentosa and PRO-015 is a gene vector that codes the human proinsulin gene indicated for Retinitis Pigmentosa. The company was founded by Stuart Medina in 2007 and is headquartered in Noain, Spain.

Medlumics SL provides medical imaging diagnostics services. It specializes in optically guided medical devices. The firm’s proprietary integrated optics platform technology combines optical and electrical components in a miniature chip, enabling for the first time complex multi view optical probes of the size of a grain of rice and ultra-portable, hand-held OCT systems that produces real-time images. The company was founded by Eduardo Margallo Balbás and Jose Luis Rubio Guivernau on April 3, 2009 and is headquartered in Tres Cantos, Spain.